With the government presenting DRDO-developed drug 2-DG as a potential game-changer in the fight against COVID-19, the clinical trial registry data suggests that the phase-3 trials for the medicine at over two dozen government and private hospitals and involving 220 patients may continue till August. The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients. While 2-DG has been studied in more than 200 clinical trials for the treatment of various cancers globally, trials to use it as a COVID-19 drug are apparently being done in India only and incidentally, a strong case for its therapeutic use against the novel coronavirus was made in a study paper last year that had Patanjali Research Institute s Acharya Balkrishna as the lead author.
The third-phase trials began in January, while the phase-2 trials were conducted over a three-month period between June and September last year and involved 110 patients.
Complaint against Baba Ramdev for mocking COVID-19 patients
In a video, Ramdev had said that patients “just don’t know how to breathe properly” and are “spreading negativity” by complaining of shortage of oxygen.
By News Desk| Published: 11th May 2021 6:23 pm IST Yoga guru Baba Ramdev. (Photo: Siasat)
Indian Medical Association (IMA) Vice President Dr Navjot Singh Dahiya has lodged a complaint against Baba Ramdev for his statements mocking COVID-19 patients who require oxygen support.
In a viral video where Baba Ramdev was seen mocking the patients, he had said that patients “just don’t know how to breathe properly” and are “spreading negativity” by complaining of shortage of oxygen.
May 10, 2021, 13:54 PM IST
New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that has been developed by Defence Research and Development Organisation (DRDO) and been given an emergency use nod by Drugs Controller General of India s (DCGI), was first studied by Patanjali researchers, claimed Acharya Balkrishna on Sunday (May 9, 2021).
A day after the DCGI granted permission for the Emergency Use of this drug as an adjunct therapy in moderate to severe COVID-19 patients, Acharya Balkrishna said, We take immense pride that Patanjali has been the pioneer centre-stone for most of the researches conducted for COVID-19.
Balkrishna, MD of Patanjali Ayurved Ltd and co-founder of Patanjali Yogpeeth in Haridwar, also shared a picture of his research paper, co-authored with three other researchers.
Indian Medical Association VP complains against Ramdev over Covid claims
SECTIONS
Last Updated: May 10, 2021, 09:14 PM IST
Share
Synopsis
In his complaint, Dr Dahiya alleged that they indulged in propaganda suggesting that people should not seek treatment from doctors, using insulting language towards doctors and intentionally and deliberately violating directions for the treatment of Covid-19 affected patients. He urged the police commissioner to conduct a high-level inquiry into the issue and said a criminal case should be registered against the accused.
Agencies
Submitting video clips of Baba Ramdev with his complaint, Dahiya alleged that he advised Covid patients to not go to hospitals for treatment but cure their symptoms themselves by following his advice.